Penn researchers are developing new treatments using mRNA technology to combat a range of diseases, namely celiac disease ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

A Navy veteran recently said that an experimental immunotherapy treatment and his faith both played key roles in helping him defeat cancer.

The woman, who had neuroblastoma as a child, had two healthy pregnancies since undergoing the trial, which uses modified ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a case-based session ...

Imugene's trial programs could result in the first 'off the shelf' Car-T therapy that uses healthy donors' cells. ... Read ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma ...

Triple-negative breast cancer (TNBC) is an aggressive form of the disease that accounts for 15% of all breast cancer cases.

The Penn physician-researcher has received more funding to advance his 'Trojan horse' for attacking gastroesophageal cancer.